Strategies for mitigating adverse events related to selective RET inhibitors in patients with RET-altered cancers
Mirella Nardo(The University of Texas MD Anderson Cancer Center), Vivek Subbiah(Sarah Cannon), Anna Poullard(The University of Texas MD Anderson Cancer Center), J. Hoyt Slade(The University of Texas MD Anderson Cancer Center), Mohamed A. Gouda(The University of Texas MD Anderson Cancer Center), Mimi I. Hu(The University of Texas MD Anderson Cancer Center), Maria E. Cabanillas(The University of Texas MD Anderson Cancer Center), Blessie Elizabeth Nelson(The University of Texas MD Anderson Cancer Center), CARMELIA MARIA NOIA BARRETO(The University of Texas MD Anderson Cancer Center), Mark Zafereo(The University of Texas MD Anderson Cancer Center)
Cited by 22
Related Papers
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|835
Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers
|New England Journal of Medicine|2020|766
2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer
|Thyroid|2021|699
Precision Targeted Therapy with BLU-667 for <i>RET</i>-Driven Cancers
|Cancer Discovery|2018|392